Aarti Pharmalabs Clarifies Disclosure Delay to BSE

Aarti Pharmalabs Limited explains delay in regulatory disclosure due to official being on leave from February 3-5, 2026, causing inadvertent breach of 24-hour timeline.

Aarti Pharmalabs Corrects Dividend Record Date Notice

Aarti Pharmalabs Limited issues corrigendum to fix typographical error in dividend record date intimation, correcting financial year reference from FY25 to FY26.

Aarti Pharmalabs Q3FY26 Results Show Mixed Performance

Aarti Pharmalabs reported Q3FY26 operational revenue of INR 4,253 Mn with EBITDA of INR 1,030 Mn. Company faces operational challenges at Atali facility while expanding Xanthine capacity to 9,000+ MTPA.

Aarti Pharmalabs Allots 10,457 Equity Shares Under PSOP

Aarti Pharmalabs Limited allotted 10,457 equity shares to employees under its Performance Stock Option Plan 2023, increasing paid-up capital to Rs. 45,32,88,755 representing 9,06,57,751 shares.

Aarti Pharmalabs faces Rs 2.60 lakh CGST penalty

Aarti Pharmalabs Limited receives penalty from CGST and Central Excise authority over alleged excess Input Tax Credit availment and incorrect tax liability declaration for FY2022-23 and FY2023-24.